Kureasia Pharma Voriconazole 200 mg is a broad-spectrum antifungal medication formulated to provide potent and reliable treatment against a wide range of serious fungal infections. Belonging to the triazole class of antifungal agents, Voriconazole works by inhibiting fungal cytochrome P450-dependent 14α-lanosterol demethylation, an essential step in ergosterol biosynthesis — a key component of fungal cell membranes. The inhibition of ergosterol synthesis results in the disruption of cell membrane integrity and ultimately leads to the death of the fungal cell, thereby controlling infection effectively.
Kureasia Pharma’s Voriconazole 200 mg is designed to offer high bioavailability and consistent therapeutic action, ensuring effective systemic absorption and optimal plasma concentration. It is indicated for the treatment of severe fungal infections including invasive aspergillosis, candidemia in non-neutropenic patients, disseminated Candida infections, and infections caused by Scedosporium and Fusarium species in patients intolerant to or refractory to other antifungal therapies. This makes Voriconazole a preferred choice in managing life-threatening mycoses, particularly in immunocompromised individuals or patients undergoing organ transplantation, chemotherapy, or prolonged corticosteroid therapy.
Each tablet of Kureasia Pharma Voriconazole 200 mg is manufactured under strict quality standards to ensure purity, potency, and safety. The formulation is designed to achieve rapid onset of action and sustained antifungal activity, providing clinicians and patients with confidence in treatment efficacy. The tablet form offers convenient oral administration and is suitable for both hospital and outpatient settings.
Pharmacokinetically, Voriconazole exhibits excellent oral absorption, with or without food, and has predictable dose-proportional plasma concentrations. It is extensively metabolized in the liver via CYP2C19, CYP2C9, and CYP3A4 enzymes, leading to multiple inactive metabolites. The elimination half-life supports twice-daily dosing, which ensures continuous suppression of fungal proliferation.
Clinically, Voriconazole 200 mg has shown superior efficacy compared to conventional antifungal agents such as amphotericin B, particularly in invasive aspergillosis, with a favorable safety and tolerability profile. Commonly reported side effects include transient visual disturbances, skin rash, nausea, and elevated liver enzymes, which are generally mild and reversible upon discontinuation or dose adjustment.
Kureasia Pharma prioritizes therapeutic excellence by combining advanced formulation technology with rigorous quality assurance, ensuring that each batch of Voriconazole meets global pharmaceutical standards. Its reliability and clinical effectiveness make it a vital antifungal therapy in hospitals and specialty care centers.
Voriconazole 200 mg by Kureasia Pharma stands as a trusted antifungal solution, offering clinicians a potent tool for combating serious systemic fungal infections and ensuring patient recovery with enhanced safety, efficacy, and consistency.
Key Features:
Broad-spectrum antifungal efficacy
Superior absorption and bioavailability
Effective against Aspergillus, Candida, and emerging fungal pathogens
Proven clinical outcomes in invasive mycoses
Manufactured to stringent GMP and WHO quality standards
Convenient oral dosage for ease of administration
Kureasia Pharma continues to uphold its commitment to advancing antifungal therapy with Voriconazole 200 mg, delivering dependable treatment outcomes for patients worldwide